Evolution and Treatments of Chronic Inflammatory Systemic Diseases

Evolution and Treatments of Chronic Inflammatory Systemic Diseases: Implementation of a Hospital Cohort in the Gastroenterology, Dermatology and Rheumatology Departments of the University Hospital of Besançon

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04191395

Acronym

MISTIC

Enrollment

3000

Registered

2019-12-09

Start date

2019-12-11

Completion date

2029-12-31

Last updated

2024-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Rheumatoid, Crohn Disease, Inflammatory Bowel Diseases, Psoriasis, Psoriatic Arthritis, Spondyloarthritis, Ulcerative Colitis, Verneuil's Disease

Brief summary

Patients with chronic inflammatory diseases (CID) followed in gastroenterology, dermatology and rheumatology have physiopathological, epidemiological and therapeutic focal points. The pathologies concerned are inflammatory bowel diseases (IBD - Crohn's disease \[MC\] and ulcerative colitis \[RCH\]), chronic inflammatory skin diseases (psoriasis or Verneuil's disease) and chronic inflammatory rheumatic diseases (rheumatoid arthritis \[RA\] and spondyloarthritis \[SpA\] including psoriatic arthritis \[PsA\]). Presenting one of these diseases is associated with a higher risk of having a second inflammatory pathology, whether the latter is ophthalmological, dermatological, rheumatological or gastroenterological. An association of extra-articular manifestations is observed in 10 to 30% of patients with SpA, and an association of extra-intestinal manifestations is observed in approximately 30% of patients with IBD. No common database for chronic systemic inflammatory diseases currently exists in France.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients treated for IBD (MC, UC or indeterminate colitis) in the gastroenterology department of Besançon University Hospital * Subject meeting the clinical, morphological and histological diagnostic criteria for MC, UC or indeterminate colitis or * Patients treated for chronic inflammatory rheumatism (RA, SpA, PsA) in the rheumatology department of the University Hospital of Besançon Subject meeting the ACR 2010 classification criteria of RA or modified New York criteria of Ankylosing spondylitis or ASAS criteria of axial or peripheral SpA or CASPAR criteria of PsA or * Patients treated for chronic inflammatory skin disease (Psoriasis, Verneuil's disease) in the dermatology department of the University Hospital of Besançon

Exclusion criteria

* Opposition of the patient * Patients in emergency situation, persons deprived of their liberty, protected minors or adults.

Design outcomes

Primary

Measure	Time frame
Diagnosis of a second inflammatory disease	through study completion (up to 10 years)

Countries

France

Contacts

Primary ContactCharline Vauchy, PhD

cvauchy@chu-besancon.fr0381218875

Backup ContactStéphanie François

sfrancois@chu-besançon.fr

Outcome results